Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026
Same author

CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

Neuro-oncology advances·2026
Same author

Cellular heterogeneity and therapeutic response profiling of human IDH + glioma stem cell cultures.

Scientific reports·2025
Same author

Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma.

Neuro-oncology·2025
Same author

Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.

Neuro-oncology·2025
Same author

Importance of radiation-related cognitive decline in older adults who receive cranial radiation.

Expert review of anticancer therapy·2025

Related Experiment Video

Updated: Jun 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?

Jerome J Graber1, Antonio Omuro

  • 1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

CNS Drugs
|June 9, 2011
PubMed
Summary

High-dose chemotherapy improves survival for primary CNS lymphoma (PCNSL). New chemotherapy combinations are needed to reduce neurotoxicity and improve long-term remission, especially for elderly patients.

Related Experiment Videos

Last Updated: Jun 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

  • Neuro-oncology
  • Hematology
  • Radiation Oncology

Background:

  • High-dose methotrexate chemotherapy with whole-brain radiotherapy improves survival in primary CNS lymphoma (PCNSL).
  • Radiotherapy-induced delayed neurotoxicity is a significant concern, particularly in elderly patients.
  • Omitting radiotherapy reduces progression-free survival, necessitating improved chemotherapy regimens.

Purpose of the Study:

  • To review current chemotherapy options for newly diagnosed and refractory PCNSL.
  • To discuss the role of alternative consolidation treatments.
  • To explore future perspectives and ongoing clinical trials.

Main Methods:

  • Review of published studies on chemotherapy for PCNSL.
  • Analysis of recent clinical trials and ongoing research.
  • Discussion of treatment strategies including drug combinations and consolidation therapies.

Main Results:

  • Chemotherapy combinations may offer advantages over single-agent methotrexate.
  • Optimal chemotherapy regimens and alternative consolidation treatments require further definition.
  • Ongoing trials aim to establish more effective and less toxic treatment protocols.

Conclusions:

  • Effective chemotherapy is crucial for improving long-term remission in PCNSL.
  • Balancing efficacy with reduced neurotoxicity is a key challenge.
  • Further research into novel drug combinations and consolidation strategies is essential for advancing PCNSL treatment.